Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University Hospital Muenster |
---|---|
Information provided by: | University Hospital Muenster |
ClinicalTrials.gov Identifier: | NCT00102284 |
The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: levodopa Drug: rivastigmine Drug: pergolid Drug: modafinil |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Improved Language Acquisition Through Neuromodulation, Project Stage Ia |
Estimated Enrollment: | 100 |
Study Start Date: | March 2004 |
Estimated Study Completion Date: | April 2005 |
Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether a mixed d1/d2 dopamine agonist (pergolid) or cholinergic neuromodulation (rivastigmine) or a general centrally arousing substance (modafinil) will yield a learning enhancement comparable to using levodopa in healthy subjects.
Our results show that the dopamine agonist pergolide impaired learning in healthy subjects compared to placebo, whereas cholinergic neuromodulation had no effect.
Ages Eligible for Study: | 20 Years to 35 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany, Nordrhein-Westfalen | |
Dept. of Neurology, University Hospital Muenster | |
Muenster, Nordrhein-Westfalen, Germany, 48129 |
Study Director: | Caterina Breitenstein, PhD | Dept. of Neurology, University Hospital Muenster |
Study Chair: | Stefan Knecht, MD | Dept. of Neurology, University Hospital Muenster |
Study ID Numbers: | KS-NEUROMOD_01, Stage Ia, IZKF Muenster: Kne3/074/04 |
Study First Received: | January 26, 2005 |
Last Updated: | September 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00102284 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
language acquisition plasticity stroke recovery associative learning |
Levodopa Rivastigmine Cerebral Infarction |
Stroke Healthy Modafinil |
Cholinesterase Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs Enzyme Inhibitors |
Cholinergic Agents Central Nervous System Agents Protective Agents Neuroprotective Agents Pharmacologic Actions |